Small Airway Dysfunction in Asthma: Associations with Control and Quality of Life.
- 1Department of Pulmonology, Mersin University Faculty of Medicine, Mersin, Türkiye.
- 2Department of Biostatistics, Mersin University Faculty of Medicine, Mersin, Türkiye.
Abstract
Objective
Small airway dysfunction (SAD) is an important but frequently underrecognized component of asthma. This study aimed to determine the prevalence of SAD in asthma, as assessed by impulse oscillometry (IOS), and to evaluate its association with clinical outcomes.Material and methods
This cross-sectional study, with a 12-month prospective follow-up, included adult patients with asthma. SAD was defined by IOS as R5-R20 ≥0.07 kPa·s·L-¹. The asthma control test (ACT) and the asthma quality of life questionnaire (AQLQ) were administered. Exacerbations were prospectively recorded during the 12 months after enrollment. Patients were stratified according to the presence of SAD. Clinical and functional parameters were compared between groups.Results
SAD was identified in 63 of 98 participants (64.3%). SAD prevalence differed significantly across the five Global Initiative for Asthma treatment steps (P < 0.001). Patients with SAD had significantly lower ACT scores (P = 0.021), poorer quality of life (AQLQ, P = 0.002), and more frequent exacerbations (P < 0.001) than those without SAD. In multivariable regression analyses, higher R5-R20 was independently associated with a lower AQLQ score (β = -0.18, 95% confidence interval -0.30 to -0.07; P = 0.002) and higher odds of being in a worse asthma control category (odds ratio 1.33, P = 0.010).Conclusion
SAD is common among patients with asthma and is associated with poorer asthma control, lower quality of life, and an increased exacerbation burden. Higher R5-R20 remained associated with poorer quality of life after adjustment for spirometry, whereas its association with asthma control was attenuated and became non-significant after adjustment for forced expiratory volume in the first second. These findings support further evaluation of IOS-defined SAD as a potentially clinically relevant trait in asthma.
Related
- Mitochondrial dysfunction in asthma: damage signals sustain airway inflammation and remodeling
- Anti-Nectin4 monoclonal antibodies attenuate airway inflammation and epithelial barrier dysfunction in asthma
- FABP4 and L-acetylcarnitine as candidate biomarkers for small airway dysfunction in children with obese type 2 asthma: a pilot cross-sectional multi-omics study.
- Relapsing Polychondritis With Severe Airway Involvement Mimicking Refractory Asthma: A Diagnostic Challenge
- Allergen-induced increases in adipocytokines: linking airway and systemic inflammation in asthma
BibTeX
@article{yulug2026small,
title = {{Small Airway Dysfunction in Asthma: Associations with Control and Quality of Life.}},
author = {Demet Polat Yuluğ and Sibel Naycı and Bahar Taşdelen and Eylem Sercan Özgür and Cengiz Özge},
journal = {Thoracic research and practice},
year = {2026},
month = oct,
doi = {10.4274/thoracrespract.2026.2026-1-7},
url = {https://europepmc.org/article/MED/42840719},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Small Airway Dysfunction in Asthma: Associations with Control and Quality of Life.
AU - Demet Polat Yuluğ
AU - Sibel Naycı
AU - Bahar Taşdelen
AU - Eylem Sercan Özgür
AU - Cengiz Özge
PY - 2026
DA - 2026/10/07
JO - Thoracic research and practice
DO - 10.4274/thoracrespract.2026.2026-1-7
UR - https://europepmc.org/article/MED/42840719
AB - Objective Small airway dysfunction (SAD) is an important but frequently underrecognized component of asthma. This study aimed to determine the prevalence of SAD in asthma, as assessed by impulse oscillometry (IOS), and to evaluate its association with clinical outcomes.Material and methods This cross-sectional study, with a 12-month prospective follow-up, included adult patients with asthma. SAD was defined by IOS as R5-R20 ≥0.07 kPa·s·L-¹. The asthma control test (ACT) and the asthma quality of life questionnaire (AQLQ) were administered. Exacerbations were prospectively recorded during the 12 months after enrollment. Patients were stratified according to the presence of SAD. Clinical and functional parameters were compared between groups.Results SAD was identified in 63 of 98 participants (64.3%). SAD prevalence differed significantly across the five Global Initiative for Asthma treatment steps (P < 0.001). Patients with SAD had significantly lower ACT scores (P = 0.021), poorer quality of life (AQLQ, P = 0.002), and more frequent exacerbations (P < 0.001) than those without SAD. In multivariable regression analyses, higher R5-R20 was independently associated with a lower AQLQ score (β = -0.18, 95% confidence interval -0.30 to -0.07; P = 0.002) and higher odds of being in a worse asthma control category (odds ratio 1.33, P = 0.010).Conclusion SAD is common among patients with asthma and is associated with poorer asthma control, lower quality of life, and an increased exacerbation burden. Higher R5-R20 remained associated with poorer quality of life after adjustment for spirometry, whereas its association with asthma control was attenuated and became non-significant after adjustment for forced expiratory volume in the first second. These findings support further evaluation of IOS-defined SAD as a potentially clinically relevant trait in asthma.
SN - 2979-9139
ER -